CA3246231A1 - TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBONOTHIOATE AND METHODS OF USE - Google Patents

TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBONOTHIOATE AND METHODS OF USE

Info

Publication number
CA3246231A1
CA3246231A1 CA3246231A CA3246231A CA3246231A1 CA 3246231 A1 CA3246231 A1 CA 3246231A1 CA 3246231 A CA3246231 A CA 3246231A CA 3246231 A CA3246231 A CA 3246231A CA 3246231 A1 CA3246231 A1 CA 3246231A1
Authority
CA
Canada
Prior art keywords
receptor
chemical
compound
group
aryl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246231A
Other languages
English (en)
French (fr)
Inventor
Jillian M. Hagel
Kaveh MATINKHOO
Peter J. Facchini
Original Assignee
Enveric Biosciences Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveric Biosciences Canada Inc filed Critical Enveric Biosciences Canada Inc
Priority claimed from PCT/CA2022/051266 external-priority patent/WO2023173197A1/en
Publication of CA3246231A1 publication Critical patent/CA3246231A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3246231A 2022-03-18 2022-08-22 TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBONOTHIOATE AND METHODS OF USE Pending CA3246231A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263321440P 2022-03-18 2022-03-18
US63/321,440 2022-03-18
US202263347835P 2022-06-01 2022-06-01
US63/347,835 2022-06-01
PCT/CA2022/051266 WO2023173197A1 (en) 2022-03-18 2022-08-22 C4-carbonothioate-substituted tryptamine derivatives and methods of using

Publications (1)

Publication Number Publication Date
CA3246231A1 true CA3246231A1 (en) 2023-09-21

Family

ID=93294636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246231A Pending CA3246231A1 (en) 2022-03-18 2022-08-22 TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBONOTHIOATE AND METHODS OF USE

Country Status (5)

Country Link
US (1) US20250206701A1 (enExample)
EP (1) EP4493542A4 (enExample)
JP (1) JP2025510666A (enExample)
AU (1) AU2022447256A1 (enExample)
CA (1) CA3246231A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4174016B2 (ja) * 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
US8349898B2 (en) * 2008-11-18 2013-01-08 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US12590065B2 (en) * 2017-04-14 2026-03-31 Zevra Therapeutics, Inc. Levorphanol prodrugs and processes for making and using them
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
DK4172145T3 (da) * 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
AU2021328726A1 (en) * 2020-08-21 2023-03-02 Compass Pathfinder Limited Novel psilocin derivatives having prodrug properties

Also Published As

Publication number Publication date
EP4493542A1 (en) 2025-01-22
AU2022447256A1 (en) 2024-11-07
US20250206701A1 (en) 2025-06-26
JP2025510666A (ja) 2025-04-15
EP4493542A4 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
US20250205197A1 (en) Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
JP5437473B2 (ja) Ａｍｐａ及びｎｍｄａ受容体モジュレーターとして使用するベンゾチアジアゼピン誘導体
US11707447B1 (en) C4-carbonothioate-substituted tryptamine derivatives and methods of using
EP3303323B1 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
US20230398097A1 (en) Carboxylated psilocybin derivatives and methods of using
TW200304817A (en) Chemical compounds
CA2187429A1 (en) N-(3-pyrrolidinyl)benzamide derivative
US11945778B2 (en) C4-carbonothioate-substituted tryptamine derivatives and methods of using
WO2020103939A1 (zh) 三唑并环类化合物、其制备方法、中间体和应用
US20250206701A1 (en) C4-carbonothioate-substituted tryptamine derivatives and methods of using
US20250197351A1 (en) C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4676600A1 (en) Protein kinase inhibitors and uses thereof
AU2015218135B2 (en) GPR142 agonist compounds
US7662750B2 (en) Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds
US12577232B2 (en) N-heterocycle substituted tryptamine derivatives and methods of using
US12195439B1 (en) C1-substituted isopropylamine fused heterocyclic mescaline derivatives
WO2026050773A1 (en) Protein kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240918

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240926

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240926

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250827

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260602